Company Overview and News

 
Sit, stay, $500 a day: Animal models earn their keep in TV, films and ad campaigns

2017-07-01 theage.com.au
Amy Peller, a marketing consultant who lives in Hoboken, New Jersey, was in the flagship Banana Republic store in London last winter when she looked up and recognised the model whose picture greeted her.
Upvote Downvote

 
Sit, stay, $500 a day: Animal models earn their keep in TV, films and ad campaigns

2017-07-01 smh.com.au
Amy Peller, a marketing consultant who lives in Hoboken, New Jersey, was in the flagship Banana Republic store in London last winter when she looked up and recognised the model whose picture greeted her.
Upvote Downvote

 
CESAR® Brand Is Bringing Holiday Sweaters To The Dogs With The Help Of Ice-T, Mark Ballas And Devon Still

2016-12-05 prnewswire
FRANKLIN, Tenn., Dec. 5, 2016 /PRNewswire/ -- This season holiday sweaters are back in a big way!  CESAR® Brand has introduced its newest holiday campaign, "Matchy-Matchy," and with the help of actor and rapper, Ice-T; dancer, musician and actor Mark Ballas; and NFL player, Devon Still, they're showing how matchy sweaters can take dogs from man's best friend to man's cool side kick. "Matchy-Matchy," created by advertising agency AMV BBDO, features a series of short-form videos, engaging social content, support from celebs and social influencers, and a contest giving dog owners a chance to get matchy-matchy with their furry friends.
Upvote Downvote

 
Mars Petcare US Announces Voluntary Recall Of Limited Number Of Cesar® Classics Filet Mignon Flavor Wet Dog Food Because Of Potential Presence Of Plastic

2016-10-07 prnewswire
FRANKLIN, Tenn., Oct. 7, 2016 /PRNewswire/ -- Today, Mars Petcare US announced a voluntary recall of a limited number of CESAR® Classics Filet Mignon Flavor product due to a potential choking risk from hard white pieces of plastic which entered the food during the production process. CESAR® Classics Filet Mignon can be purchased individually, as well as, in flavor variety multipacks. The Lot Codes listed below are the only affected products.
Upvote Downvote

 
5 Tips to Bond with Your Dog this Fall

2016-10-05 prnewswire
MISSION, Kan., Oct. 5, 2016 /PRNewswire/ -- (Family Features) Dogs are up for anything. They're your "pawtners" in crime, ready to take on new activities or just the standard walk down the street. Every activity is more fun with a four-legged best friend by your side. As fall settles in, it's a perfect time to try out new adventures. Here are five things you can do this fall with your dog.
Upvote Downvote

 
Mars Petcare Brings Wet Dog Food Portfolio Together To Drive Category Growth

2016-05-05 prnewswire
NASHVILLE, Tenn., May 5, 2016 /PRNewswire/ -- Mars Petcare, the leader of the wet dog food category, is bringing together its portfolio of wet dog food brands – CESAR®, PEDIGREE®, NUTRO™ and IAMS™ – to grow the wet food category.  Mix Mania is the new creative campaign launching today as a collaboration among these four brands to increase the overall awareness of wet dog food and create growth by spotlighting the most common usage occasion, encouraging dog owners to MIX IN wet food with dry kibble, and LOOK OUT for mealtime excitement and a doggy freak out face to remember.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...